Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN)

Kidney International, Supplement

Volumn 66, Issue 92, 2004, Pages

  Remuzzi, Giuseppe ^a   Chiurchiu, Carlos ^b   Ruggenenti, Piero ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b NONE

Author keywords

ACE inhibition; Remission; Renal protection

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; GLOMERULUS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; NEPHROTOXICITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SYSTEMATIC REVIEW; ULTRAFILTRATION; CHRONIC KIDNEY FAILURE; PREDICTION AND FORECASTING; REVIEW; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; PREDICTIVE VALUE OF TESTS; PROTEINURIA; TREATMENT OUTCOME;

EID: 16644399486     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.09221.x     Document Type: Article

References (41)

1. LYSAGHT MJ: Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol 13:S37-40, 2002
2. SCHIEPPATI A, PERICO N, REMUZZI G: Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. Nephrol Dial Transplant 18:858-859, 2003
3. XUE JL, MA JZ, LOUIS TA, COLLINS AJ: Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 12:2753-2758, 2001
4. SCHIEPPATI A, REMUZZI G: Fighting renal diseases in poor countries: Building a global fund with the help of the pharmaceutical industry. J Am Soc Nephrol 15:704-707, 2004
5. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
6. CAMPBELL RC, RUGGENENTI P, REMUZZI G: Halting the progression of chronic nephropathy. J Am Soc Nephrol 13(Suppl 3):S190-195, 2002
7. REMUZZI G, RUGGENENTI P, PERICO N: Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med 16:604-615, 2002
8. PISONI R, RUGGENENTI P, REMUZZI G: Renoprotective therapy in patients with nondiabetic nephropathies. Drugs 61:733-745, 2001
9. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
10. ABBATE M, BENIGNI A, BERTANI T, REMUZZI G: Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 14:304-312, 1999
11. BERTANI T, CUTILLO F, ZOJA C, et al: Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 30:488-496, 1986
12. BERTANI T, ZOJA C, ABBATE M, et al: Age-related nephropathy and proteinuria in rats with intact kidney exposed to diets with different protein options. Lab Invest 60:196-204, 1989
13. ABBATE M, ZOJA C, MORIGI M, et al: Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: A central pathway in progressive glomerulosclerosis. Am J Pathol 161:2179-2199, 2002
14. ROSSING P, HOMMEL E, SMIDT UM, PARVING H-H: Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42:715-719, 1993
15. RUGGENENTI P, PERNA A, MOSCONI L, et al, ON BEHALF OF THE "GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA" (GISEN): Urinary protein excretion rate is the best independent predictor to ESRF in non-diabetic chronic nephropathies. Kidney Int 57:1209-1216, 1998
16. TARVER-CARR ME, BRANCATI FL, EBERHARDT MS, POWE NR: Proteinuria and the risk of chronic kidney disease (CKD) in the United States. J Am Soc Nephrol 11:168A, 2000
17. HOY WE, WANG Z, VANBUYNDER P, et al: The natural history of renal disease in Australian Aborigines. Part 1. Changes in albuminuria and glomerular filtration rate over time. Kidney Int 60(1):243-248, 2001
18. ISEKI K, KINJO K, ISEKI C, TAKISHITA S: Relationship between predicted GFR and proteinuria on the risk of developing ESRD in Okinawa, Japan. Kidney Int, in press
19. ZUCCHELLI P, ZUCCALÀ A, BORGHI M, et al: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
20. KAMPER AL, STRANDGAARD S, LEYSSAC PP: Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial. Am J Hypertens 5:423-430, 1992
21. HANNEDOUCHE T, LANDAIS P, GOLDFARB B, et al: Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 309:833-837, 1994
22. BANNISTER KM, WEAVER A, CLARKSON AR, WOODROFFE AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111:184-192, 1995
23. MASCHIO G, ALBERTI D, JANIN G, et al: Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 11; 334:939-945, 1996
24. MAKI DD, MA JZ, LOUIS TA, KASISKE BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 155:1073-1080, 1995
25. GANSEVOORT RT, SLUITER WJ, HEMMELDER MH, et al: Antiproteinuric effect of blood-pressure-lowering agents: A meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963-1974, 1995
26. GIATRAS I, LAU J, LEVEY AS: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 127:337-345, 1997
27. THE GISEN GROUP (GRUPPO ITALIANO DI STUDI EPIDEMIOLOGICI IN NEFROLOGIA): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
28. GASPARI F, PERICO N, RUGGENENTI P, et al: Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol 6:257-263, 1995
29. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352:1252-1256, 1998
30. RUGGENENTI P, PERNA A, GHERARDI G, et al: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with nonnephrotic proteinuria. Lancet 354:359-364, 1999
31. RUGGENENTI P, PERNA A, REMUZZI G, GISEN GROUP INVESTIGATORS: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63:2254-2261, 2003
32. RUGGENENTI P, PERNA A, BENINI R, et al: In chronic nephropathies prolonged ACE inhibition can induce remission: Dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia. J Am Soc Nephrol 10:997-1006, 1999
33. RUGGENENTI P, SCHIEPPATI A, REMUZZI G: Progression, remission, regression of chronic renal diseases. Lancet 357:1601-1608, 2001
34. RUGGENENTI P, PERNA A, ZOCCALI C, et al: Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen). J Am Soc Nephrol 11:88-96, 2000
35. JAFAR TH, STARK PC, SCHMID CH, et al: Angiotensin-converting enzyme inhibition and progression of renal disease: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. AIPRD Study Group. Kidney Int 60:1131-1140, 2001
36. JAFAR TH, SCHMID CH, LANDA M, et al, FOR THE ACE INHIBITION IN PROGRESSIVE RENAL DISEASE STUDY GROUP. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
37. JAFAR TH, STARK PC, SCHMID CH, et al, AIPRD STUDY GROUP: Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 139:244-252, 2003
38. KLAHR S, LEVEY AS, BECK GJ, et al: The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
39. WRIGHT, JT, JR., BAKRIS G, GREENE T, et al: African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288:2421-2431, 2002
40. JAFAR TH, SCHMID CH, STARK PC, et al: The rate of progression of renal disease may not be slower in women compared with men: A patient-level meta-analysis. Nephrol Dial Transplant 18:2047-2053, 2003
41. NEUGARTEN J, ACHARYA A, SILBIGER SR: Effect of gender on the progression of nondiabetic renal disease: A meta-analysis. J Am Soc Nephrol 11:319-329, 2000